These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34250834)

  • 81. Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID).
    Absalón-Aguilar A; Rull-Gabayet M; Pérez-Fragoso A; Mejía-Domínguez NR; Núñez-Álvarez C; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; González-Lara F; Martín-Nares E; Montesinos-Ramírez S; Ramírez-Alemón M; Ramírez-Rangel P; Márquez MF; Plata-Corona JC; Juárez-Vega G; Gómez-Martín D; Torres-Ruiz J
    J Gen Intern Med; 2022 Jan; 37(1):4-14. PubMed ID: 34755269
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Colchicine for cardiovascular medicine: a systematic review and meta-analysis.
    Casula M; Andreis A; Avondo S; Vaira MP; Imazio M
    Future Cardiol; 2022 Aug; 18(8):647-659. PubMed ID: 35787150
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review.
    Sharaf S; Ashmawy R; Saleh E; Salama M; El-Maradny YA; Zari A; Aly S; Tolba A; Mahrous D; Elsayed H; Latif D; Redwan EM; Kamal E
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241167
    [No Abstract]   [Full Text] [Related]  

  • 84. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
    Bonifácio LP; Ramacciotti E; Agati LB; Vilar FC; Silva ACTD; Louzada Júnior P; Fonseca BALD; Souza HCC; Oliveira CCC; Aguiar VCR; Quadros CAA; Dusilek C; Itinose K; Risson R; Ferreira LRR; Lopes RD; Kallas EG; Bellissimo-Rodrigues F
    Rev Soc Bras Med Trop; 2023; 56():e0565. PubMed ID: 37075454
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
    Eikelboom JW; Jolly SS; Belley-Cote EP; Whitlock RP; Rangarajan S; Xu L; Heenan L; Bangdiwala SI; Tarhuni WM; Hassany M; Kontsevaya A; Harper W; Sharma SK; Lopez-Jaramillo P; Dans AL; Palileo-Villanueva LM; Avezum A; Pais P; Xavier D; Felix C; Yusufali A; Lopes RD; Berwanger O; Ali Z; Wasserman S; Anand SS; Bosch J; Choudhri S; Farkouh ME; Loeb M; Yusuf S
    Lancet Respir Med; 2022 Dec; 10(12):1160-1168. PubMed ID: 36228639
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The evidence from clinical trials on colchicine and corticosteroids' effect on COVID-19: a systematic review and meta-analysis.
    Bitar AN; Sulaiman SAS
    Curr Med Res Opin; 2022 Dec; 38(12):2097-2108. PubMed ID: 35819071
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.
    Pandolfi S; Chirumbolo S; Ricevuti G; Valdenassi L; Bjørklund G; Lysiuk R; Doşa MD; Lenchyk L; Fazio S
    Basic Clin Pharmacol Toxicol; 2022 Feb; 130(2):225-239. PubMed ID: 34811895
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
    Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
    Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.
    Imazio M; Brucato A; Lazaros G; Andreis A; Scarsi M; Klein A; De Ferrari GM; Adler Y
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):625-629. PubMed ID: 32658005
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome.
    Lutschinger LL; Rigopoulos AG; Schlattmann P; Matiakis M; Sedding D; Schulze PC; Noutsias M
    BMC Cardiovasc Disord; 2019 Sep; 19(1):207. PubMed ID: 31477020
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Colchicine in Stable Coronary Artery Disease.
    Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
    Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Colchicine in prevention of atrial fibrillation following cardiac surgery: systematic review and meta-analysis.
    Trivedi C; Sadadia M
    Indian J Pharmacol; 2014; 46(6):590-5. PubMed ID: 25538328
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 96. Colchicine and myocardial infarction: A review.
    Akodad M; Sicard P; Fauconnier J; Roubille F
    Arch Cardiovasc Dis; 2020 Oct; 113(10):652-659. PubMed ID: 32712201
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Efficacy and safety of colchicine in the treatment of acute myocardial infarction: A protocol for systematic review and meta-analysis.
    Xiong H; Huang X; Rao L; Zhao J
    Medicine (Baltimore); 2021 Apr; 100(14):e25429. PubMed ID: 33832144
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.
    Lien CH; Lee MD; Weng SL; Lin CH; Liu LY; Tai YL; Lei WT; Liu JM; Huang YN; Chi H; Chiu NC; Lin CY
    Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440608
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study.
    Deftereos S; Giannopoulos G; Panagopoulou V; Bouras G; Raisakis K; Kossyvakis C; Karageorgiou S; Papadimitriou C; Vastaki M; Kaoukis A; Angelidis C; Pagoni S; Pyrgakis V; Alexopoulos D; Manolis AS; Stefanadis C; Cleman MW
    JACC Heart Fail; 2014 Apr; 2(2):131-7. PubMed ID: 24720919
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.